Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease

Table 1

Serum level of sirolimus during treatment.

Date of dosage (year/month/day)	Dose (mg/d)	Sirolimus level (ug/L)
08.10.15	0.5	5.6
08.12.03	0.5	4
09.01.21	0.5	6.2
09.02.27	0.5	5.1
09.07.08	0.5	5.6
09.09.16	0.5	4.2
09.09.30	0.5	3.7
09.09.10	0.5	2.8
09.11.04	1	10.5
09.11.18	0.5	4.3
10.01.22	0.5	3
10.05.12	0.5	5.3
10.06.02	0.5	3.1
10.06.23	0.5	3.8